Fig. 6
Comparison of metabolic activation systems in the PMR-W-treated TA1537 strain in the Ames test. The mean of the number of revertant colonies in the absence and presence of the 5% Aroclor1254-induced rat S9, 5% human liver S9, 5% and 10% CYP1A1 bactosome (instead of liver s9); combination of 5% human liver S9 and 5% CYP1A1 bactosome; and 10%, 20%, and 40% in vivo BaP-treated rat liver S9 are shown in (A). The BaP responses are shown in (B). 2AA 0.5 μg/plate (S9 positive control), 9AA 50 μg/plate (positive control), and BaP (Aroclor 1254-induced rat S9 positive control) were treated with positive control.
